tradingkey.logo

Helius Medical Technologies Inc

HSDT

24.130USD

+0.960+4.14%
Close 09/19, 16:00ETQuotes delayed by 15 min
328.41KMarket Cap
LossP/E TTM

Helius Medical Technologies Inc

24.130

+0.960+4.14%
More Details of Helius Medical Technologies Inc Company
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
Company Info
Ticker SymbolHSDT
Company nameHelius Medical Technologies Inc
IPO dateJun 27, 2014
CEOMr. Dane C. Andreeff
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 27
Address642 Newtown Yardley Road
CityNEWTOWN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code18940
Phone12159446100
Websitehttps://heliusmedical.com/
Ticker SymbolHSDT
IPO dateJun 27, 2014
CEOMr. Dane C. Andreeff
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
15.00
-6.25%
Mr. Blane Walter
Mr. Blane Walter
Independent Director
Independent Director
3.00
--
Mr. Paul Buckman
Mr. Paul Buckman
Independent Director
Independent Director
2.00
--
Dr. Antonella Favit-Van Pelt, M.D., Ph.D.
Dr. Antonella Favit-Van Pelt, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Sherrie Perkins
Ms. Sherrie Perkins
Independent Director
Independent Director
--
--
Vice Adm. (Retd.) Edward M. (Ed) Straw
Vice Adm. (Retd.) Edward M. (Ed) Straw
Independent Director
Independent Director
--
--
Mr. Dane C. Andreeff
Mr. Dane C. Andreeff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Joseph Chee
Dr. Joseph Chee
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Mr. Jeffrey S. (Jeff) Mathiesen, CPA
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
15.00
-6.25%
Mr. Blane Walter
Mr. Blane Walter
Independent Director
Independent Director
3.00
--
Mr. Paul Buckman
Mr. Paul Buckman
Independent Director
Independent Director
2.00
--
Dr. Antonella Favit-Van Pelt, M.D., Ph.D.
Dr. Antonella Favit-Van Pelt, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Sherrie Perkins
Ms. Sherrie Perkins
Independent Director
Independent Director
--
--
Vice Adm. (Retd.) Edward M. (Ed) Straw
Vice Adm. (Retd.) Edward M. (Ed) Straw
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
19.00K
38.78%
United States
19.00K
38.78%
Other revenue
11.00K
22.45%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 24
Updated: Sun, Aug 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wealthspire Advisors LLC
0.56%
Desjardins Securities Inc.
0.37%
Leonite Fund I LP
0.30%
Baader Bank AG
0.09%
UBS Financial Services, Inc.
0.07%
Other
98.61%
Shareholders
Shareholders
Proportion
Wealthspire Advisors LLC
0.56%
Desjardins Securities Inc.
0.37%
Leonite Fund I LP
0.30%
Baader Bank AG
0.09%
UBS Financial Services, Inc.
0.07%
Other
98.61%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.63%
Research Firm
0.37%
Corporation
0.32%
Investment Advisor/Hedge Fund
0.09%
Family Office
0.02%
Hedge Fund
0.02%
Other
98.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
37
12.45K
1.83%
+11.99K
2025Q1
40
16.72K
1.11%
-2.03K
2024Q4
43
261.97K
7.03%
-14.04K
2024Q3
43
183.78K
9.58%
-95.02K
2024Q2
46
285.33K
12.75%
+168.92K
2024Q1
47
120.01K
13.52%
+4.71K
2023Q4
50
81.05K
12.51%
-44.86K
2023Q3
52
56.40K
16.69%
-20.37K
2023Q2
56
42.39K
14.78%
-10.21K
2023Q1
55
22.24K
15.26%
-34.89K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Leonite Fund I LP
3.26K
0.47%
+3.26K
--
Jun 05, 2025
L1 Capital Global Opportunities Master Fund Ltd.
4.28K
0.61%
+4.28K
--
Jun 06, 2025
Independent Financial Partners
7.00
0%
--
--
Mar 31, 2025
Tower Research Capital LLC
5.00
0%
-2.00
-28.57%
Mar 31, 2025
Maple Leaf Partners, L.P.
44.00
0.01%
-1.00
-2.22%
May 02, 2025
Intracoastal Capital, L.L.C.
16.00
0%
+16.00
--
May 14, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Dec 31, 2020
Merger
35→1
Dec 31, 2020
Merger
35→1
Date
Type
Ratio
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Aug 16, 2023
Merger
50→1
Dec 31, 2020
Merger
35→1
Dec 31, 2020
Merger
35→1
Dec 31, 2020
Merger
35→1
Dec 31, 2020
Merger
35→1
KeyAI